Earnings Report | 2026-05-24 | Quality Score: 92/100
Earnings Highlights
EPS Actual
-0.87
EPS Estimate
-0.33
Revenue Actual
Revenue Estimate
***
{平台标识} {固定描述} My Size Inc. (MYSZ) reported Q4 2025 earnings per share (EPS) of -$0.87, significantly below the consensus estimate of -$0.3264, resulting in a negative surprise of -166.54%. The company did not report any revenue for the quarter, with both actual and estimated revenue listed as none. Despite the earnings miss, the stock rose 1.03% in after-hours trading.
Management Commentary
MYSZ -{平台标识} {随机描述} {随机描述} My Size Inc., a technology company specializing in sizing and measurement solutions, delivered Q4 2025 results that reflected ongoing operational challenges. The reported EPS of -$0.87 implies that operating expenses exceeded the prior quarter’s run-rate and analyst expectations, though the exact drivers remain under review. With no revenue reported, the company appears to still be in a pre-revenue or early-stage commercialization phase, where spending on R&D, sales, and general administration may continue to outpace any limited revenue generation. The lack of top-line data suggests the company has not yet achieved meaningful sales traction from its flagship products, such as its mobile sizing algorithms or e-commerce integration tools. Margins were not disclosed due to the absence of revenue, making it difficult to assess cost efficiency. The negative EPS surprise of 166.54% highlights a material deviation from Wall Street’s expectations, potentially driven by higher-than-anticipated operating expenditures or one-time charges. Without revenue or segment breakdowns, investors will need to scrutinize the full 10-K filing for a clearer picture of cash burn and operational milestones.
MYSZ Q4 2025 Earnings: EPS Misses Estimates, No Revenue Reported {随机描述}{随机描述}MYSZ Q4 2025 Earnings: EPS Misses Estimates, No Revenue Reported {随机描述}{随机描述}
Forward Guidance
MYSZ -{平台标识} {随机描述} {随机描述} My Size did not provide any formal guidance for fiscal 2026 or update its strategic outlook during the Q4 2025 release. Given the significant earnings miss, management may need to address cost-control measures and prioritize capital preservation. The company could focus on accelerating commercialization efforts, such as licensing its sizing technology to retailers or expanding partnerships, though any revenue growth remains uncertain. Strategic priorities may include reducing cash burn through operational efficiencies while continuing to invest in product development. Risk factors include a limited revenue base, potential need for additional financing, and competitive pressure from alternative sizing solutions. The absence of revenue and the large EPS surprise raise questions about the company’s near-term viability. Investors should watch for any forward-looking statements in subsequent filings or press releases, as well as updates on patent progress or pilot programs. The lack of guidance suggests that management may be reassessing its timeline to market and may adopt a more conservative outlook pending further commercialization milestones.
MYSZ Q4 2025 Earnings: EPS Misses Estimates, No Revenue Reported {随机描述}{随机描述}MYSZ Q4 2025 Earnings: EPS Misses Estimates, No Revenue Reported {随机描述}{随机描述}
Market Reaction
MYSZ -{平台标识} {随机描述} {随机描述} Despite the sharp EPS miss and zero revenue reported, MYSZ stock rose 1.03% in after-hours trading, indicating that some investors may have already priced in a weak quarter or are focused on potential future catalysts. Analyst reactions have not yet been published, but the magnitude of the negative surprise could prompt downgrades or price target revisions. The stock’s positive move may reflect covering of short positions or speculation about a turnaround—but with no revenue, the company remains highly speculative. What to watch next: the company’s cash position, any progress on commercial agreements, and whether management provides a timeline for achieving first meaningful revenue. The upcoming annual report (10-K) will be critical for understanding operating burn rate and balance sheet health. Given the lack of top-line growth and the significant EPS deviation, the risk profile for My Size appears elevated. Investors should exercise caution and await clearer signs of revenue generation before reassessing the investment thesis. Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.
MYSZ Q4 2025 Earnings: EPS Misses Estimates, No Revenue Reported {随机描述}{随机描述}MYSZ Q4 2025 Earnings: EPS Misses Estimates, No Revenue Reported {随机描述}{随机描述}